PULSE BIOSCIENCES, INC. — Investor Relations & Filings

Pulse Biosciences, Inc. is a bioelectric medicine company developing its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology. This non-thermal energy platform delivers nanosecond-duration electrical pulses to ablate cellular tissue while sparing adjacent noncellular structures. The company's primary focus is on advancing treatments in cardiology, particularly for atrial fibrillation, through investigational devices such as the CellFX® nsPFA™ 360 Cardiac Catheter and a surgical cardiac clamp. Pulse Biosciences is also developing its technology for non-cardiac applications, including the use of percutaneous electrodes for treating conditions like benign thyroid nodules. The nsPFA technology aims to provide a potentially safer and more efficient alternative to conventional thermal ablation methods across a broad spectrum of medical procedures.